Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition

Srikumar M. Raja, Swapnil S. Desale, Bhopal Mohapatra, Haitao Luan, Kruti Soni, Jinjin Zhang, Matthew A. Storck, Dan Feng, Timothy A. Bielecki, Vimla Band, Samuel Monroe Cohen, Tatiana K Bronich, Hamid Band

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Targeted delivery of anticancer drugs to tumor cells using monoclonal antibodies against oncogenic cell surface receptors is an emerging therapeutic strategy. These strategies include drugs directly conjugated to monoclonal antibodies through chemical linkers (Antibody-Drug Conjugates, ADCs) or those encapsulated within nanoparticles that in turn are conjugated to targeting antibodies (Antibody-Nanoparticle Conjugates, ANPs). The recent FDA approval of the ADC Trastuzumab-TDM1 (Kadcyla®; Genentech; San Francisco) for the treatment of ErbB2-overexpressing metastatic breast cancer patients has validated the strong potential of these strategies. Even though the activity of ANPs and ADCs is dependent on lysosomal traffic, the roles of the endocytic route traversed by the targeted receptor and of cancer cell-specific alterations in receptor dynamics on the efficiency of drug delivery have not been considered in these new targeted therapies. For example, constitutive association with the molecular chaperone HSP90 is thought to either retard ErbB2 endocytosis or to promote its recycling, traits undesirable for targeted therapy with ANPs and ADCs. HSP90 inhibitors are known to promote ErbB2 ubiquitination, targeting to lysosome and degradation. We therefore hypothesized that ErbB2-targeted drug delivery using Trastuzumab-conjugated nanoparticles could be significantly improved by HSP90 inhibitor-promoted lysosomal traffic of ErbB2. Studies reported here validate this hypothesis and demonstrate, both in vitro and in vivo, that HSP90 inhibition facilitates the intracellular delivery of Trastuzumab-conjugated ANPs carrying a model chemotherapeutic agent, Doxorubicin, specifically into ErbB2-overexpressing breast cancer cells, resulting in improved antitumor activity. These novel findings highlight the need to consider oncogene-specific alterations in receptor traffic in the design of targeted drug delivery strategies. We suggest that combination of agents that enhance receptor endocytosis and lysosomal routing can provide a novel strategy to significantly improve therapy with ANPs and ADCs.

Original languageEnglish (US)
Pages (from-to)10522-10535
Number of pages14
JournalOncotarget
Volume7
Issue number9
DOIs
StatePublished - Jan 1 2016

Fingerprint

Atrial Natriuretic Factor
Antibodies
Pharmaceutical Preparations
Nanoparticles
Endocytosis
Monoclonal Antibodies
Breast Neoplasms
Therapeutics
Drug Approval
Molecular Chaperones
San Francisco
Drug Design
Ubiquitination
Recycling
Cell Surface Receptors
Lysosomes
Oncogenes
Doxorubicin
Neoplasms
Trastuzumab

Keywords

  • Breast cancer
  • ErbB2
  • HSP90
  • Targeted drug delivery
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology

Cite this

Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. / Raja, Srikumar M.; Desale, Swapnil S.; Mohapatra, Bhopal; Luan, Haitao; Soni, Kruti; Zhang, Jinjin; Storck, Matthew A.; Feng, Dan; Bielecki, Timothy A.; Band, Vimla; Cohen, Samuel Monroe; Bronich, Tatiana K; Band, Hamid.

In: Oncotarget, Vol. 7, No. 9, 01.01.2016, p. 10522-10535.

Research output: Contribution to journalArticle

Raja, SM, Desale, SS, Mohapatra, B, Luan, H, Soni, K, Zhang, J, Storck, MA, Feng, D, Bielecki, TA, Band, V, Cohen, SM, Bronich, TK & Band, H 2016, 'Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition', Oncotarget, vol. 7, no. 9, pp. 10522-10535. https://doi.org/10.18632/oncotarget.7231
Raja, Srikumar M. ; Desale, Swapnil S. ; Mohapatra, Bhopal ; Luan, Haitao ; Soni, Kruti ; Zhang, Jinjin ; Storck, Matthew A. ; Feng, Dan ; Bielecki, Timothy A. ; Band, Vimla ; Cohen, Samuel Monroe ; Bronich, Tatiana K ; Band, Hamid. / Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. In: Oncotarget. 2016 ; Vol. 7, No. 9. pp. 10522-10535.
@article{d637d230298c41f591cca476630aeb2d,
title = "Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition",
abstract = "Targeted delivery of anticancer drugs to tumor cells using monoclonal antibodies against oncogenic cell surface receptors is an emerging therapeutic strategy. These strategies include drugs directly conjugated to monoclonal antibodies through chemical linkers (Antibody-Drug Conjugates, ADCs) or those encapsulated within nanoparticles that in turn are conjugated to targeting antibodies (Antibody-Nanoparticle Conjugates, ANPs). The recent FDA approval of the ADC Trastuzumab-TDM1 (Kadcyla{\circledR}; Genentech; San Francisco) for the treatment of ErbB2-overexpressing metastatic breast cancer patients has validated the strong potential of these strategies. Even though the activity of ANPs and ADCs is dependent on lysosomal traffic, the roles of the endocytic route traversed by the targeted receptor and of cancer cell-specific alterations in receptor dynamics on the efficiency of drug delivery have not been considered in these new targeted therapies. For example, constitutive association with the molecular chaperone HSP90 is thought to either retard ErbB2 endocytosis or to promote its recycling, traits undesirable for targeted therapy with ANPs and ADCs. HSP90 inhibitors are known to promote ErbB2 ubiquitination, targeting to lysosome and degradation. We therefore hypothesized that ErbB2-targeted drug delivery using Trastuzumab-conjugated nanoparticles could be significantly improved by HSP90 inhibitor-promoted lysosomal traffic of ErbB2. Studies reported here validate this hypothesis and demonstrate, both in vitro and in vivo, that HSP90 inhibition facilitates the intracellular delivery of Trastuzumab-conjugated ANPs carrying a model chemotherapeutic agent, Doxorubicin, specifically into ErbB2-overexpressing breast cancer cells, resulting in improved antitumor activity. These novel findings highlight the need to consider oncogene-specific alterations in receptor traffic in the design of targeted drug delivery strategies. We suggest that combination of agents that enhance receptor endocytosis and lysosomal routing can provide a novel strategy to significantly improve therapy with ANPs and ADCs.",
keywords = "Breast cancer, ErbB2, HSP90, Targeted drug delivery, Trastuzumab",
author = "Raja, {Srikumar M.} and Desale, {Swapnil S.} and Bhopal Mohapatra and Haitao Luan and Kruti Soni and Jinjin Zhang and Storck, {Matthew A.} and Dan Feng and Bielecki, {Timothy A.} and Vimla Band and Cohen, {Samuel Monroe} and Bronich, {Tatiana K} and Hamid Band",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.7231",
language = "English (US)",
volume = "7",
pages = "10522--10535",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "9",

}

TY - JOUR

T1 - Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition

AU - Raja, Srikumar M.

AU - Desale, Swapnil S.

AU - Mohapatra, Bhopal

AU - Luan, Haitao

AU - Soni, Kruti

AU - Zhang, Jinjin

AU - Storck, Matthew A.

AU - Feng, Dan

AU - Bielecki, Timothy A.

AU - Band, Vimla

AU - Cohen, Samuel Monroe

AU - Bronich, Tatiana K

AU - Band, Hamid

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Targeted delivery of anticancer drugs to tumor cells using monoclonal antibodies against oncogenic cell surface receptors is an emerging therapeutic strategy. These strategies include drugs directly conjugated to monoclonal antibodies through chemical linkers (Antibody-Drug Conjugates, ADCs) or those encapsulated within nanoparticles that in turn are conjugated to targeting antibodies (Antibody-Nanoparticle Conjugates, ANPs). The recent FDA approval of the ADC Trastuzumab-TDM1 (Kadcyla®; Genentech; San Francisco) for the treatment of ErbB2-overexpressing metastatic breast cancer patients has validated the strong potential of these strategies. Even though the activity of ANPs and ADCs is dependent on lysosomal traffic, the roles of the endocytic route traversed by the targeted receptor and of cancer cell-specific alterations in receptor dynamics on the efficiency of drug delivery have not been considered in these new targeted therapies. For example, constitutive association with the molecular chaperone HSP90 is thought to either retard ErbB2 endocytosis or to promote its recycling, traits undesirable for targeted therapy with ANPs and ADCs. HSP90 inhibitors are known to promote ErbB2 ubiquitination, targeting to lysosome and degradation. We therefore hypothesized that ErbB2-targeted drug delivery using Trastuzumab-conjugated nanoparticles could be significantly improved by HSP90 inhibitor-promoted lysosomal traffic of ErbB2. Studies reported here validate this hypothesis and demonstrate, both in vitro and in vivo, that HSP90 inhibition facilitates the intracellular delivery of Trastuzumab-conjugated ANPs carrying a model chemotherapeutic agent, Doxorubicin, specifically into ErbB2-overexpressing breast cancer cells, resulting in improved antitumor activity. These novel findings highlight the need to consider oncogene-specific alterations in receptor traffic in the design of targeted drug delivery strategies. We suggest that combination of agents that enhance receptor endocytosis and lysosomal routing can provide a novel strategy to significantly improve therapy with ANPs and ADCs.

AB - Targeted delivery of anticancer drugs to tumor cells using monoclonal antibodies against oncogenic cell surface receptors is an emerging therapeutic strategy. These strategies include drugs directly conjugated to monoclonal antibodies through chemical linkers (Antibody-Drug Conjugates, ADCs) or those encapsulated within nanoparticles that in turn are conjugated to targeting antibodies (Antibody-Nanoparticle Conjugates, ANPs). The recent FDA approval of the ADC Trastuzumab-TDM1 (Kadcyla®; Genentech; San Francisco) for the treatment of ErbB2-overexpressing metastatic breast cancer patients has validated the strong potential of these strategies. Even though the activity of ANPs and ADCs is dependent on lysosomal traffic, the roles of the endocytic route traversed by the targeted receptor and of cancer cell-specific alterations in receptor dynamics on the efficiency of drug delivery have not been considered in these new targeted therapies. For example, constitutive association with the molecular chaperone HSP90 is thought to either retard ErbB2 endocytosis or to promote its recycling, traits undesirable for targeted therapy with ANPs and ADCs. HSP90 inhibitors are known to promote ErbB2 ubiquitination, targeting to lysosome and degradation. We therefore hypothesized that ErbB2-targeted drug delivery using Trastuzumab-conjugated nanoparticles could be significantly improved by HSP90 inhibitor-promoted lysosomal traffic of ErbB2. Studies reported here validate this hypothesis and demonstrate, both in vitro and in vivo, that HSP90 inhibition facilitates the intracellular delivery of Trastuzumab-conjugated ANPs carrying a model chemotherapeutic agent, Doxorubicin, specifically into ErbB2-overexpressing breast cancer cells, resulting in improved antitumor activity. These novel findings highlight the need to consider oncogene-specific alterations in receptor traffic in the design of targeted drug delivery strategies. We suggest that combination of agents that enhance receptor endocytosis and lysosomal routing can provide a novel strategy to significantly improve therapy with ANPs and ADCs.

KW - Breast cancer

KW - ErbB2

KW - HSP90

KW - Targeted drug delivery

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84961642239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961642239&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7231

DO - 10.18632/oncotarget.7231

M3 - Article

C2 - 26859680

AN - SCOPUS:84961642239

VL - 7

SP - 10522

EP - 10535

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 9

ER -